%0 Journal Article %A TAKASHI KATO %A TARO OSHIKIRI %A HIRONOBU GOTO %A RYUICHIRO SAWADA %A HITOSHI HARADA %A NAOKI URAKAWA %A HIROSHI HASEGAWA %A SHINGO KANAJI %A KIMIHIRO YAMASHITA %A TAKERU MATSUDA %A YOSHIHIRO KAKEJI %T Impact of the Platelet-to-Lymphocyte Ratio as a Biomarker for Esophageal Squamous Cell Carcinoma %D 2022 %R 10.21873/anticanres.15757 %J Anticancer Research %P 2775-2782 %V 42 %N 5 %X Background/Aim: Esophageal squamous cell carcinoma (ESCC) is a deadly malignant disease. This study examined whether the platelet-to-lymphocyte ratio (PLR) can be used as a biomarker to evaluate prognosis in patients with advanced ESCC following neoadjuvant chemotherapy (NAC) and undergoing minimally invasive esophagectomy (MIE). Patients and Methods: We examined 174 patients between January 2010 and December 2015 at the Kobe University. Of these, 121 were treated with NAC. The PLR cutoff was determined through receiver-operating characteristic curve analysis. Univariate and multivariate analyses were conducted to identify prognostic factors for overall survival (OS). Results: The PLR cutoff for OS in 121 patients was 169.6. Patients with PLR ≥169.6 had worse 5-year OS rates (31.1%) than those with a PLR <169.6 (61.1%, p=0.001). Multivariate analysis revealed that a PLR of ≥169.6 was an independent factor for poor prognosis. Conclusion: PLR is an independent prognostic factor for patients with ESCC after NAC and MIE. %U https://ar.iiarjournals.org/content/anticanres/42/5/2775.full.pdf